Panacos Pharmaceuticals, Inc. engages in the discovery and development of small-molecule oral drug which is designed to treat human immunodeficiency virus and other major human viral diseases. The company is headquartered in Watertown, Massachusetts and currently employs 41 full-time employees. The firm's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The firm has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Follow-Up Questions
Panacos Pharmaceuticals Inc (PANC)의 PER은 얼마입니까?
Panacos Pharmaceuticals Inc의 PER은 0입니다
Panacos Pharmaceuticals Inc의 CEO는 누구입니까?
Dr. Alan Dunton은 2007부터 회사에 합류한 Panacos Pharmaceuticals Inc의 President입니다.
PANC 주식의 가격 성능은 어떻습니까?
PANC의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Panacos Pharmaceuticals Inc의 주요 사업 주제나 업종은 무엇입니까?
Panacos Pharmaceuticals Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
